Publicaciones Recientes – Alma Delia Campos Parra

Potential miRNA Use as a Biomarker: From Breast Cancer Diagnosis to Metastasis. Jordan-Alejandre E, Campos-Parra AD, Castro-López DL, Silva-Cázares MB. Cells. 2023 Feb 6;12(4):525. doi: 10.3390/cells12040525. PMID: 36831192

Molecular Differences between Squamous Cell Carcinoma and Adenocarcinoma Cervical Cancer Subtypes: Potential Prognostic Biomarkers. Campos-Parra AD, Pérez-Quintanilla M, Martínez-Gutierrez AD, Pérez-Montiel D, Coronel-Martínez J, Millan-Catalan O, De León DC, Pérez-Plasencia C. Curr Oncol. 2022 Jul 5;29(7):4689-4702. doi: 10.3390/curroncol29070372. PMID: 35877232

LncRNAs driving feedback loops to boost drug resistance: sinuous pathways in cancer. Sánchez-Marín D, Trujano-Camacho S, Pérez-Plasencia C, De León DC, Campos-Parra AD. Cancer Lett. 2022 Sep 1;543:215763. doi: 10.1016/j.canlet.2022.215763. Epub 2022 Jun 7. PMID: 35680071

Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer. Contreras-Romero C, Pérez-Yépez EA, Martinez-Gutierrez AD, Campos-Parra A, Zentella-Dehesa A, Jacobo-Herrera N, López-Camarillo C, Corredor-Alonso G, Martínez-Coronel J, Rodríguez-Dorantes M, de León DC, Pérez-Plasencia C. Front Oncol. 2022 Mar 3;12:773438. doi: 10.3389/fonc.2022.773438. eCollection 2022. PMID: 35359376

A microRNA panel that regulates proinflammatory cytokines as diagnostic and prognosis biomarkers in colon cancer. Martínez-Gutierrez A, Carbajal-Lopez B, Bui TM, Mendoza-Rodriguez M, Campos-Parra AD, Calderillo-Ruiz G, Cantú-De Leon D, Madrigal-Santillán EO, Sumagin R, Pérez-Plasencia C, Pérez-Yépez EA. Biochem Biophys Rep. 2022 Mar 18;30:101252. doi: 10.1016/j.bbrep.2022.101252. eCollection 2022 Jul. PMID: 35313644